RU2013157374A - Производное индазола и пирролопиридина и его фармацевтическое применение - Google Patents
Производное индазола и пирролопиридина и его фармацевтическое применение Download PDFInfo
- Publication number
- RU2013157374A RU2013157374A RU2013157374/04A RU2013157374A RU2013157374A RU 2013157374 A RU2013157374 A RU 2013157374A RU 2013157374/04 A RU2013157374/04 A RU 2013157374/04A RU 2013157374 A RU2013157374 A RU 2013157374A RU 2013157374 A RU2013157374 A RU 2013157374A
- Authority
- RU
- Russia
- Prior art keywords
- group
- optionally substituted
- oxadiazol
- methyl
- fluoro
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 claims abstract 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 31
- 125000001424 substituent group Chemical group 0.000 claims abstract 28
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 25
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 17
- 239000012634 fragment Substances 0.000 claims abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims 30
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 29
- 125000001072 heteroaryl group Chemical group 0.000 claims 27
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000000623 heterocyclic group Chemical group 0.000 claims 25
- 125000003545 alkoxy group Chemical group 0.000 claims 24
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 22
- 125000002619 bicyclic group Chemical group 0.000 claims 22
- 125000002252 acyl group Chemical group 0.000 claims 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 19
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 18
- 125000004043 oxo group Chemical group O=* 0.000 claims 18
- -1 phenacyl group Chemical group 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000003277 amino group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000004104 aryloxy group Chemical group 0.000 claims 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims 9
- 150000001721 carbon Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- ANJNIJQFOWNGMN-UHFFFAOYSA-N 3-(3-ethylindazol-1-yl)-5-[1-(2-methylpropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CC(C)C)CC1 ANJNIJQFOWNGMN-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- BFGQFILTMVCOFW-INIZCTEOSA-N (2s)-1-[4-[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-4-methylpiperidin-1-yl]-2-hydroxypropan-1-one Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1(C)CCN(C(=O)[C@H](C)O)CC1 BFGQFILTMVCOFW-INIZCTEOSA-N 0.000 claims 1
- MBHLLEMPOJORAC-DLBZAZTESA-N 1-[(2r)-2-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@H]1CCCN1C(=O)CO MBHLLEMPOJORAC-DLBZAZTESA-N 0.000 claims 1
- MBHLLEMPOJORAC-IRXDYDNUSA-N 1-[(2s)-2-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@@H]1CCCN1C(=O)CO MBHLLEMPOJORAC-IRXDYDNUSA-N 0.000 claims 1
- VRQZMCLLJRPDFX-INIZCTEOSA-N 1-[(2s)-2-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@@H]1CCCN1C(=O)CO VRQZMCLLJRPDFX-INIZCTEOSA-N 0.000 claims 1
- CUDONWZUXRTGLR-IAGOWNOFSA-N 1-[(3r)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@H]1CCN(C(=O)CO)C1 CUDONWZUXRTGLR-IAGOWNOFSA-N 0.000 claims 1
- CUDONWZUXRTGLR-DLBZAZTESA-N 1-[(3r)-3-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@H]1CCN(C(=O)CO)C1 CUDONWZUXRTGLR-DLBZAZTESA-N 0.000 claims 1
- DBPUJDHYTDWYKN-OAHLLOKOSA-N 1-[(3r)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@H]1CCN(C(=O)CO)C1 DBPUJDHYTDWYKN-OAHLLOKOSA-N 0.000 claims 1
- OEQYNZXSMQIWST-MRXNPFEDSA-N 1-[(3r)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-methoxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@H]1CCN(C(=O)COC)C1 OEQYNZXSMQIWST-MRXNPFEDSA-N 0.000 claims 1
- KSHNUMSXRLBXDI-MRXNPFEDSA-N 1-[(3r)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@H]1CCN(C(C)=O)C1 KSHNUMSXRLBXDI-MRXNPFEDSA-N 0.000 claims 1
- CUDONWZUXRTGLR-SJORKVTESA-N 1-[(3s)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@@H]1CCN(C(=O)CO)C1 CUDONWZUXRTGLR-SJORKVTESA-N 0.000 claims 1
- HGZOAZODDJVYTO-MSOLQXFVSA-N 1-[(3s)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC[C@H]1CN1C[C@@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 HGZOAZODDJVYTO-MSOLQXFVSA-N 0.000 claims 1
- NWJMYBCZZZLUFH-MSOLQXFVSA-N 1-[(3s)-3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]ethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@@H]1CCN(C(C)=O)C1 NWJMYBCZZZLUFH-MSOLQXFVSA-N 0.000 claims 1
- CUDONWZUXRTGLR-IRXDYDNUSA-N 1-[(3s)-3-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1C[C@@H]1CCN(C(=O)CO)C1 CUDONWZUXRTGLR-IRXDYDNUSA-N 0.000 claims 1
- HGZOAZODDJVYTO-ROUUACIJSA-N 1-[(3s)-3-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC[C@H]1CN1C[C@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 HGZOAZODDJVYTO-ROUUACIJSA-N 0.000 claims 1
- DBPUJDHYTDWYKN-HNNXBMFYSA-N 1-[(3s)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@@H]1CCN(C(=O)CO)C1 DBPUJDHYTDWYKN-HNNXBMFYSA-N 0.000 claims 1
- OEQYNZXSMQIWST-INIZCTEOSA-N 1-[(3s)-3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]pyrrolidin-1-yl]-2-methoxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@@H]1CCN(C(=O)COC)C1 OEQYNZXSMQIWST-INIZCTEOSA-N 0.000 claims 1
- OUFSOXKXMOXXLL-OAHLLOKOSA-N 1-[3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]-2-hydroxyethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1CC1CN(C(=O)CO)C1 OUFSOXKXMOXXLL-OAHLLOKOSA-N 0.000 claims 1
- RLZYHVVQPIAASE-MRXNPFEDSA-N 1-[3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC1CN1C[C@@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 RLZYHVVQPIAASE-MRXNPFEDSA-N 0.000 claims 1
- PFDBLDXPCWBDIO-MRXNPFEDSA-N 1-[3-[[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]ethanone Chemical compound C([C@@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)C(C)C)CN1CC1CN(C(C)=O)C1 PFDBLDXPCWBDIO-MRXNPFEDSA-N 0.000 claims 1
- RLZYHVVQPIAASE-INIZCTEOSA-N 1-[3-[[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]methyl]azetidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC1CN1C[C@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 RLZYHVVQPIAASE-INIZCTEOSA-N 0.000 claims 1
- BAJCMSHWHVWULL-UHFFFAOYSA-N 1-[3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CN(C(=O)CO)C1 BAJCMSHWHVWULL-UHFFFAOYSA-N 0.000 claims 1
- BQPBKRHIEZFMSQ-UHFFFAOYSA-N 1-[3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]-2-methoxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CN(C(=O)COC)C1 BQPBKRHIEZFMSQ-UHFFFAOYSA-N 0.000 claims 1
- ZWYWLDXUNIOMHJ-UHFFFAOYSA-N 1-[3-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CN(C(C)=O)C1 ZWYWLDXUNIOMHJ-UHFFFAOYSA-N 0.000 claims 1
- LWJGQBHNVKVSHJ-UHFFFAOYSA-N 1-[3-[[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]azetidin-1-yl]-2-methoxyethanone Chemical compound C1N(C(=O)COC)CC1CN1CCC(C=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 LWJGQBHNVKVSHJ-UHFFFAOYSA-N 0.000 claims 1
- OOYQGQXAIOWLDW-QGZVFWFLSA-N 1-[4-[(3r)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]piperidin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCC1N1C[C@@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 OOYQGQXAIOWLDW-QGZVFWFLSA-N 0.000 claims 1
- NIBZFXWOZKSFIT-INIZCTEOSA-N 1-[4-[(3s)-3-[[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]piperidin-1-yl]ethanone Chemical compound C([C@H](C1)CC=2ON=C(N=2)N2N=C(C3=CC=CC(F)=C32)CC)CN1C1CCN(C(C)=O)CC1 NIBZFXWOZKSFIT-INIZCTEOSA-N 0.000 claims 1
- OOYQGQXAIOWLDW-KRWDZBQOSA-N 1-[4-[(3s)-3-[[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl]pyrrolidin-1-yl]piperidin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCC1N1C[C@H](CC=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 OOYQGQXAIOWLDW-KRWDZBQOSA-N 0.000 claims 1
- RAVCNWHAZVFEIU-UHFFFAOYSA-N 1-[4-[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-4-methylpiperidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1(C)CCN(C(=O)CO)CC1 RAVCNWHAZVFEIU-UHFFFAOYSA-N 0.000 claims 1
- OESVOUZRYHMLHI-UHFFFAOYSA-N 1-[4-[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-4-methylpiperidin-1-yl]-2-methoxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1(C)CCN(C(=O)COC)CC1 OESVOUZRYHMLHI-UHFFFAOYSA-N 0.000 claims 1
- QSLDCXZFUZFZCZ-UHFFFAOYSA-N 1-[4-[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]piperidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(=O)CO)CC1 QSLDCXZFUZFZCZ-UHFFFAOYSA-N 0.000 claims 1
- HWKVHAKGQAKPSQ-UHFFFAOYSA-N 1-[4-[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]piperidin-1-yl]-2-methoxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(=O)COC)CC1 HWKVHAKGQAKPSQ-UHFFFAOYSA-N 0.000 claims 1
- AZHYXQUMPRMIPP-UHFFFAOYSA-N 1-[4-[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-3-methylpiperidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(=O)CO)CC1C AZHYXQUMPRMIPP-UHFFFAOYSA-N 0.000 claims 1
- FLYAKKKHKJZSAG-UHFFFAOYSA-N 1-[4-[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-3-methylpiperidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(C)=O)CC1C FLYAKKKHKJZSAG-UHFFFAOYSA-N 0.000 claims 1
- MUMXSJKRTMAHIN-UHFFFAOYSA-N 1-[4-[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]piperidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(=O)CO)CC1 MUMXSJKRTMAHIN-UHFFFAOYSA-N 0.000 claims 1
- OXJXZHXXGNJMTA-UHFFFAOYSA-N 1-[4-[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]piperidin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCC1N1CCC(C=2ON=C(N=2)N2C3=C(F)C=CC=C3C(C(C)C)=N2)CC1 OXJXZHXXGNJMTA-UHFFFAOYSA-N 0.000 claims 1
- QWAPFRNMUGMNHY-UHFFFAOYSA-N 1-[4-[4-[3-(7-fluoro-3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]piperidin-1-yl]ethanone Chemical compound C12=C(F)C=CC=C2C(C(C)C)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCN(C(C)=O)CC1 QWAPFRNMUGMNHY-UHFFFAOYSA-N 0.000 claims 1
- KSRNURQSWQDXOM-UHFFFAOYSA-N 1-[4-[[4-[3-(3-ethyl-7-fluoroindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methyl]piperidin-1-yl]-2-hydroxyethanone Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CCN(C(=O)CO)CC1 KSRNURQSWQDXOM-UHFFFAOYSA-N 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- LSSGAMFKGPXTSG-UHFFFAOYSA-N 3-(3-cyclobutylindazol-1-yl)-5-[1-(2-methylpropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C1CN(CC(C)C)CCC1C1=NC(N2C3=CC=CC=C3C(C3CCC3)=N2)=NO1 LSSGAMFKGPXTSG-UHFFFAOYSA-N 0.000 claims 1
- UPEWACUKDKPZFZ-UHFFFAOYSA-N 3-(3-cyclopropylindazol-1-yl)-5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C1CN(CCCOC)CCC1C1=NC(N2C3=CC=CC=C3C(C3CC3)=N2)=NO1 UPEWACUKDKPZFZ-UHFFFAOYSA-N 0.000 claims 1
- HOTSKDJTIYFOFX-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-(1-propan-2-ylpiperidin-4-yl)-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(C(C)C)CC1 HOTSKDJTIYFOFX-UHFFFAOYSA-N 0.000 claims 1
- KVMDFFICDUBQIA-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCOC)CC1 KVMDFFICDUBQIA-UHFFFAOYSA-N 0.000 claims 1
- XYXXNTSJPOTJPD-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-[1-(oxan-4-ylmethyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CCOCC1 XYXXNTSJPOTJPD-UHFFFAOYSA-N 0.000 claims 1
- SIUIIWXMVCWPFU-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-[1-(oxolan-3-yl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C1CCOC1 SIUIIWXMVCWPFU-UHFFFAOYSA-N 0.000 claims 1
- GHTJFFIPTCBHEG-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-[1-[2-(oxan-4-yl)ethyl]piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CCC1CCOCC1 GHTJFFIPTCBHEG-UHFFFAOYSA-N 0.000 claims 1
- GKWJZAWUHKCMAR-UHFFFAOYSA-N 3-(3-ethyl-6-fluoroindazol-1-yl)-5-[1-[2-(oxolan-2-yl)ethyl]piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC(F)=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CCC1CCCO1 GKWJZAWUHKCMAR-UHFFFAOYSA-N 0.000 claims 1
- QNWXFSNRRTYHBM-UHFFFAOYSA-N 3-(3-ethyl-7-fluoroindazol-1-yl)-5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCOC)CC1 QNWXFSNRRTYHBM-UHFFFAOYSA-N 0.000 claims 1
- PBFWIRJENZTYLS-OAHLLOKOSA-N 3-(3-ethyl-7-fluoroindazol-1-yl)-5-[1-[[(3r)-1-methylsulfonylpyrrolidin-3-yl]methyl]piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@H]1CCN(S(C)(=O)=O)C1 PBFWIRJENZTYLS-OAHLLOKOSA-N 0.000 claims 1
- PBFWIRJENZTYLS-HNNXBMFYSA-N 3-(3-ethyl-7-fluoroindazol-1-yl)-5-[1-[[(3s)-1-methylsulfonylpyrrolidin-3-yl]methyl]piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=C(F)C=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1C[C@@H]1CCN(S(C)(=O)=O)C1 PBFWIRJENZTYLS-HNNXBMFYSA-N 0.000 claims 1
- QDGPBSMDNXXFIY-UHFFFAOYSA-N 3-(3-ethylindazol-1-yl)-5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCOC)CC1 QDGPBSMDNXXFIY-UHFFFAOYSA-N 0.000 claims 1
- IHAYQKGJNWCNNG-UHFFFAOYSA-N 3-(3-ethylindazol-1-yl)-5-[1-(oxolan-2-ylmethyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CCCO1 IHAYQKGJNWCNNG-UHFFFAOYSA-N 0.000 claims 1
- VXZCTHDZGQPRNB-UHFFFAOYSA-N 3-(3-propan-2-ylindazol-1-yl)-5-(1-propylpiperidin-4-yl)-1,2,4-oxadiazole Chemical compound C1CN(CCC)CCC1C1=NC(N2C3=CC=CC=C3C(C(C)C)=N2)=NO1 VXZCTHDZGQPRNB-UHFFFAOYSA-N 0.000 claims 1
- BWNJKRFSQWSCLZ-UHFFFAOYSA-N 3-[4-[3-(3-ethylindazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propan-1-ol Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C1CCN(CCCO)CC1 BWNJKRFSQWSCLZ-UHFFFAOYSA-N 0.000 claims 1
- YVYFLKAXFQVCCC-UHFFFAOYSA-N 5-(1-butan-2-ylpiperidin-4-yl)-3-(3-cyclobutylindazol-1-yl)-1,2,4-oxadiazole Chemical compound C1CN(C(C)CC)CCC1C1=NC(N2C3=CC=CC=C3C(C3CCC3)=N2)=NO1 YVYFLKAXFQVCCC-UHFFFAOYSA-N 0.000 claims 1
- UFPZJYAJNHUFSS-UHFFFAOYSA-N 5-(1-butan-2-ylpiperidin-4-yl)-3-(3-cyclopropylindazol-1-yl)-1,2,4-oxadiazole Chemical compound C1CN(C(C)CC)CCC1C1=NC(N2C3=CC=CC=C3C(C3CC3)=N2)=NO1 UFPZJYAJNHUFSS-UHFFFAOYSA-N 0.000 claims 1
- XWBWURBJEPTIHV-UHFFFAOYSA-N 5-(1-butan-2-ylpiperidin-4-yl)-3-(3-ethylindazol-1-yl)-1,2,4-oxadiazole Chemical compound C1CN(C(C)CC)CCC1C1=NC(N2C3=CC=CC=C3C(CC)=N2)=NO1 XWBWURBJEPTIHV-UHFFFAOYSA-N 0.000 claims 1
- PTCUXBSTCRMCOY-UHFFFAOYSA-N 5-[1-(2-methylpropyl)piperidin-4-yl]-3-(3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazole Chemical compound C1CN(CC(C)C)CCC1C1=NC(N2C3=CC=CC=C3C(C(C)C)=N2)=NO1 PTCUXBSTCRMCOY-UHFFFAOYSA-N 0.000 claims 1
- ZSFAZNJBEGJGAS-UHFFFAOYSA-N 5-[1-(3-methoxypropyl)piperidin-4-yl]-3-(3-propan-2-ylindazol-1-yl)-1,2,4-oxadiazole Chemical compound C1CN(CCCOC)CCC1C1=NC(N2C3=CC=CC=C3C(C(C)C)=N2)=NO1 ZSFAZNJBEGJGAS-UHFFFAOYSA-N 0.000 claims 1
- DYXGXIBMYYSRTE-UHFFFAOYSA-N 5-[1-(cyclopropylmethyl)piperidin-4-yl]-3-(3-ethylindazol-1-yl)-1,2,4-oxadiazole Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C(CC1)CCN1CC1CC1 DYXGXIBMYYSRTE-UHFFFAOYSA-N 0.000 claims 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- UKCLLWHSIKYQLW-UHFFFAOYSA-N methyl 4-[3-[3-(3-ethylindazol-1-yl)-1,2,4-oxadiazol-5-yl]azetidin-1-yl]piperidine-1-carboxylate Chemical compound C12=CC=CC=C2C(CC)=NN1C(N=1)=NOC=1C(C1)CN1C1CCN(C(=O)OC)CC1 UKCLLWHSIKYQLW-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 150000003413 spiro compounds Chemical class 0.000 claims 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 abstract 1
- BLISZBYFASHPAB-UHFFFAOYSA-N CC(C1(C)CC1)NC Chemical compound CC(C1(C)CC1)NC BLISZBYFASHPAB-UHFFFAOYSA-N 0.000 description 1
- 0 CCC(CC)N*C Chemical compound CCC(CC)N*C 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011127688 | 2011-06-07 | ||
| JP2011-127688 | 2011-06-07 | ||
| PCT/JP2012/065052 WO2012169649A1 (en) | 2011-06-07 | 2012-06-06 | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013157374A true RU2013157374A (ru) | 2015-07-20 |
Family
ID=47296200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013157374/04A RU2013157374A (ru) | 2011-06-07 | 2012-06-06 | Производное индазола и пирролопиридина и его фармацевтическое применение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140057895A1 (enExample) |
| EP (1) | EP2718283A4 (enExample) |
| JP (1) | JP2014510708A (enExample) |
| KR (1) | KR20140041519A (enExample) |
| CN (1) | CN103748087A (enExample) |
| AU (1) | AU2012267797A1 (enExample) |
| BR (1) | BR112013030939A2 (enExample) |
| CA (1) | CA2833507A1 (enExample) |
| MX (1) | MX2013014427A (enExample) |
| RU (1) | RU2013157374A (enExample) |
| TW (1) | TW201311674A (enExample) |
| WO (1) | WO2012169649A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016028016A (ja) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
| EP3290421B1 (en) | 2013-02-22 | 2019-01-02 | Pfizer Inc | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) |
| JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| KR102140508B1 (ko) | 2016-09-28 | 2020-08-03 | 경희대학교 산학협력단 | 헌팅턴병의 예방 또는 치료용 조성물 |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| AU2019238326B2 (en) | 2018-03-23 | 2025-03-06 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| KR20220007845A (ko) | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| EP3914592A1 (en) * | 2019-01-25 | 2021-12-01 | University of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (spns2) for use in therapy |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN116836157A (zh) * | 2022-03-25 | 2023-10-03 | 星希尔生物科技(上海)有限公司 | 一种噁二唑衍生物及其制备方法和用途 |
| CN115417772B (zh) * | 2022-09-26 | 2024-07-19 | 无锡双启科技有限公司 | 一种3-硝基-4-氟苯甲醚的制备方法 |
| CN115947690B (zh) * | 2022-12-13 | 2025-04-08 | 安徽医科大学 | 一种吲唑分子砌块的制备方法及其在药物合成中的应用 |
| WO2025045837A1 (en) | 2023-08-31 | 2025-03-06 | Syngenta Crop Protection Ag | Pesticidally active indazole compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1291569B1 (it) * | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| ES2347265T3 (es) * | 2004-12-22 | 2010-10-27 | Theravance, Inc. | Compuestos de indazol-carboxamida. |
| JP5075818B2 (ja) * | 2005-07-22 | 2012-11-21 | ファイザー株式会社 | ５ｈｔ４受容体アゴニストとしてのインダゾールカルボキサミド誘導体 |
| GB0614070D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| GB0901487D0 (en) * | 2009-01-30 | 2009-03-11 | Movetis N V | Asthma Therapy |
| EP2643311A1 (en) * | 2010-11-26 | 2013-10-02 | Lupin Limited | Bicyclic gpr119 modulators |
| MX337721B (es) * | 2011-09-19 | 2016-03-16 | Suven Life Sciences Ltd | Compuestos de heteroarilo como ligandos del receptor 5-ht4. |
-
2012
- 2012-06-06 WO PCT/JP2012/065052 patent/WO2012169649A1/en not_active Ceased
- 2012-06-06 BR BR112013030939A patent/BR112013030939A2/pt not_active IP Right Cessation
- 2012-06-06 EP EP12796621.6A patent/EP2718283A4/en not_active Withdrawn
- 2012-06-06 US US14/005,659 patent/US20140057895A1/en not_active Abandoned
- 2012-06-06 RU RU2013157374/04A patent/RU2013157374A/ru not_active Application Discontinuation
- 2012-06-06 KR KR1020137032070A patent/KR20140041519A/ko not_active Withdrawn
- 2012-06-06 JP JP2013547047A patent/JP2014510708A/ja active Pending
- 2012-06-06 MX MX2013014427A patent/MX2013014427A/es unknown
- 2012-06-06 CN CN201280025823.9A patent/CN103748087A/zh active Pending
- 2012-06-06 CA CA2833507A patent/CA2833507A1/en not_active Abandoned
- 2012-06-06 AU AU2012267797A patent/AU2012267797A1/en not_active Abandoned
- 2012-06-07 TW TW101120435A patent/TW201311674A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140041519A (ko) | 2014-04-04 |
| CN103748087A (zh) | 2014-04-23 |
| MX2013014427A (es) | 2014-01-23 |
| US20140057895A1 (en) | 2014-02-27 |
| AU2012267797A2 (en) | 2014-05-22 |
| CA2833507A1 (en) | 2012-12-13 |
| BR112013030939A2 (pt) | 2016-12-06 |
| JP2014510708A (ja) | 2014-05-01 |
| AU2012267797A1 (en) | 2014-01-09 |
| TW201311674A (zh) | 2013-03-16 |
| EP2718283A4 (en) | 2014-10-29 |
| WO2012169649A1 (en) | 2012-12-13 |
| EP2718283A1 (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013157374A (ru) | Производное индазола и пирролопиридина и его фармацевтическое применение | |
| JP2014510708A5 (enExample) | ||
| JP6479029B2 (ja) | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 | |
| AU2011347711B2 (en) | Indazolyl triazole derivatives as IRAK inhibitors | |
| DK2627649T3 (en) | CXCR4 receptor antagonists | |
| CA2670760A1 (en) | Naphthyridine compounds as inhibitors of akt activity | |
| JP2019525941A (ja) | ジメトキシフェニル置換インドール化合物 | |
| JP2015522036A (ja) | 脂質合成の複素環モジュレーター | |
| EP2643311A1 (en) | Bicyclic gpr119 modulators | |
| JP2018530591A5 (enExample) | ||
| JP2011500806A5 (enExample) | ||
| EA020730B1 (ru) | Производные пиримидина в качестве ингибиторов киназы | |
| JPWO2020231808A5 (enExample) | ||
| RU2013155456A (ru) | Соединения пирролидинилмочевины и пирролидинилтиомочевины как ингибиторы киназы trka | |
| JP2014525448A5 (enExample) | ||
| KR20170049609A (ko) | Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체 | |
| RU2003106193A (ru) | Способ лечения аллергий с использованием замещенных пиразолов | |
| HRP20160421T1 (hr) | Derivat azola | |
| RU2011134868A (ru) | N-замещенные насыщенные гетероциклические сульфоновые соединения с активностью агонистов рецептора св2 | |
| RU2016144202A (ru) | АНАЛОГИ СОЕДИНЕНИЙ 4Н-ПИРАЗОЛО[1,5-a]БЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ PARP | |
| JP2016513681A5 (enExample) | ||
| TW200904433A (en) | Substituted imidazole compound and use thereof | |
| KR20250008772A (ko) | 테트라하이드로이소퀴놀린 헤테로이작용성 bcl-xl 분해제 | |
| JP2018515489A5 (enExample) | ||
| JP5677457B2 (ja) | ピロリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150608 |